GLUCAGON-LIKE PEPTIDE-1 ENHANCES GLUCOSE-TOLERANCE BOTH BY STIMULATION OF INSULIN RELEASE AND BY INCREASING INSULIN-INDEPENDENT GLUCOSE DISPOSAL

Citation
Da. Dalessio et al., GLUCAGON-LIKE PEPTIDE-1 ENHANCES GLUCOSE-TOLERANCE BOTH BY STIMULATION OF INSULIN RELEASE AND BY INCREASING INSULIN-INDEPENDENT GLUCOSE DISPOSAL, The Journal of clinical investigation, 93(5), 1994, pp. 2263-2266
Citations number
24
Categorie Soggetti
Medicine, Research & Experimental
ISSN journal
00219738
Volume
93
Issue
5
Year of publication
1994
Pages
2263 - 2266
Database
ISI
SICI code
0021-9738(1994)93:5<2263:GPEGBB>2.0.ZU;2-U
Abstract
Glucagon-like peptide 1 [7-36 amide](GLP-1) has been shown to enhance insulin secretion in healthy and type II diabetic humans, and to incre ase glucose disposal in type I diabetic patients. To further define it s action on glucose kinetics, we studied six healthy subjects who rece ived either GLP-1 (45 pmol/ kg per h) or 150 mM saline on two mornings during which a modified intravenous glucose tolerance test was perfor med. Plasma insulin and glucose levels were analyzed using Bergman's m inimal model of glucose kinetics to derive indices of insulin sensitiv ity (S-I) and glucose effectiveness at basal insulin (S-G), the latter a measure of glucose disposition independent of changes in insulin. I n addition, basal insulin concentrations, the acute insulin response t o glucose (AIR(g)), plasma glucagon levels, and the glucose disappeara nce constant (K-g) were measured on the days that subjects received GL P-1 or saline. Compared with saline infusions, GLP-1 increased the mea n K-g from 1.61 +/- 0.20 to 2.65 +/- 0.25% /min (P = 0.022).The enhanc ed glucose disappearance seen with GLP-1 was in part the result of its insulinotropic effect, as indicated by a rise in AIR(g) from 240 +/- 48 to 400 +/- 78 pM (P = 0.013). However, there was also an increase i n S-G from 1.77 +/- 0.11 to 2.65 +/- 0.33 x 10(-2).min(-1) (P = 0.038) , which was accounted for primarily by insulin-independent processes, viz glucose effectiveness in the absence of insulin. There was no sign ificant effect of GLP-1 on S-I or basal insulin, and glucagon levels w ere not different during the glucose tolerance tests with or without G LP-1. Thus, GLP-1 improves glucose tolerance both through its insulino tropic action and by increasing glucose effectiveness. These findings suggest that GLP-1 has direct effects on tissues involved in glucose d isposition. Furthermore, this peptide may be useful for studying the p rocess of insulin-independent glucose disposal, and pharmacologic anal ogues may be beneficial for treating patients with diabetes mellitus.